Heterologous COVID-19 Booster Vaccination in the Chronic Disorder of Consciousness: A Pilot Study.

Autor: Pugliese, Maria Elena, Battaglia, Riccardo, Raso, Maria Girolama, Chiaravalloti, Raffaela, Coschignano, Francesco, Pagliuso, Angela, Bruschetta, Roberta, Pugliese, Giovanni, Scola, Paolo, Tonin, Paolo, Cerasa, Antonio
Předmět:
Zdroj: Clinics & Practice; Jun2022, Vol. 12 Issue 3, p318-325, 8p
Abstrakt: Significant anti-spike protein receptor-binding domain (S-RBD) antibody responses have been demonstrated in patients with chronic disorder of consciousness (DOC) completing a COVID-19 vaccine regime with BNT162b2 (Pfizer–BioNTech). We now provide further prospective data on the immunogenicity of these patients followed by heterologous booster injection with mRNA-1273 (Moderna). These patients were compared with two different demographically comparable healthcare workers (HCW) groups who underwent homologous booster injection with BNT162b2 vaccine or heterologous booster injection with mRNA-1273. Antibody responses were evaluated at 21 days after the administration of the booster dose of vaccination. Results: No severe adverse reactions were reported after each type of vaccination. Heterologous boosting with mRNA-1273 elicited a higher increase of S-RBD IgG levels than homologous boosting with BNT162b2 both in DOC patients and HCW who had previously received two doses of BNT162b2. No significant difference was detected between DOC and HCW patients who received heterologous boosting. Conclusions: Despite the small sample size, our preliminary results suggest that heterologous boosting with mRNA-1273, following initial vaccination with BNT162b2, is safe and tends to be more immunogenic than homologous boosting, either in fragile people or in healthy controls. [ABSTRACT FROM AUTHOR]
Databáze: Complementary Index
Externí odkaz:
Nepřihlášeným uživatelům se plný text nezobrazuje